Lexaria Bioscience is focusing on its pioneering DehydraTECH drug delivery technology The company boasts a portfolio of unique products Lexaria continues to conduct research regarding DehydraTECH technology for oral nicotine Based in Kelowna, British Columbia, Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) focuses on technology for the improved delivery of bioactive compounds. Lexaria is the … Continue reading “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Advancing DehydraTECH Drug Delivery Platform, Innovative Products”
Lexaria Bioscience is focusing on its unique technology for the delivery of bioactive compounds The company’s concentration on oral ingestion results in an option that often healthier than other delivery methods Its DehydraTECH technology has potential applications for nicotine absorption Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) focuses on technology for the improved delivery of … Continue reading “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Innovating on Numerous Fronts with DehydraTECH Drug Delivery Platform”
Lexaria Bioscience has its innovative DehydraTECH drug delivery platform The company’s DehydraTECH technology is complementary to other R&D being done on cannabinoids Lexaria recently attended O’Cannabiz 2018 in Vancouver A biotech company, Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) offers a unique platform that makes it possible to deliver bioactive substances through oral ingestion. Its … Continue reading “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) CEO Discusses Company Initiatives at O’Cannabiz 2018”
Lexaria’s technology changes the manner in which edible cannabinoids enter the body The company out-licenses its DehydraTECH drug delivery platform Lexaria recently announced the creation of four wholly owned subsidiaries A research-driven company, Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is the only company globally that has been awarded a patent for the improved delivery … Continue reading “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Completes Establishment of Four Wholly Owned Subsidiaries”
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) this morning announced the creation of four new wholly-owned subsidiary companies: Lexaria CanPharm Corp., a Canadian company that provides DehydraTECH technology and other enhancements to the global cannabis industry; Lexaria Nicotine Corp., a US company with a global license to offer DehydraTECH technology to the global nicotine and tobacco … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Unveils Four New Subsidiary Companies”
NetworkNewsWire Editorial Coverage: American smokers are stubbing out their cigarettes. Data from the Centers for Disease Control and Prevention (CDC) show that the proportion of the adult American population that has smoked at least 100 cigarettes during their lifetimes stood at 15.5 percent in 2016, down from 20.9 percent in 2005 (http://nnw.fm/J6dQp). Of course, quitting … Continue reading “Smokers Light Up Less, Alternative Nicotine Delivery Technologies Take Center Stage”
Lexaria has developed an oral digestion technology that may translate into lower dosages and shorter treatment regimens Company is expanding its edible product offerings through a licensing agreement with a Canadian cannabis chocolate manufacturer Lexaria continues to develop products for demonstration, testing and sales Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has developed DehydraTECH™, an … Continue reading “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Expanding Best-in-Class Product Line”
NetworkNewsWire Editorial Coverage: With the expected legalization of recreational cannabis use in Canada just months away, the Canadian cannabis industry is experiencing a frenzied flow of capital that is only likely to accelerate. While this capital rush won’t affect every company in the space, the overriding sentiment supports global aspirations and trickle-down opportunity for innovators … Continue reading “Cannabis Deals Cross the Billion-Dollar Mark in Canada”
High-margin licensing royalties of 5-10% of gross sales of its patented bioscience technology and process are an attractive valuation builder; LXRP sees more licensing opportunities in 2018 LXRP’s technology is patented in the U.S. and Australia; company has national/regional filings pending in 44 countries Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) generates revenue by out-licensing … Continue reading “Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Boosts Revenue by Out-Licensing Patented Technology to Third-Party Partners”
Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has developed delivery technologies to improve absorption of bioactive compounds and intends to use that technology in the tea market. The company plans to apply its patented DehydraTECH™ technology to supplement a range of black teas with cannabidiol (CBD) from hemp. An article discussing this reads: “Lexaria’s acquisition … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Enters the Multibillion-Dollar Tea Market”
